H.‐G. Mergenthaler

2.4k total citations
33 papers, 903 citations indexed

About

H.‐G. Mergenthaler is a scholar working on Oncology, Hematology and Genetics. According to data from OpenAlex, H.‐G. Mergenthaler has authored 33 papers receiving a total of 903 indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Oncology, 10 papers in Hematology and 8 papers in Genetics. Recurrent topics in H.‐G. Mergenthaler's work include Cancer Treatment and Pharmacology (7 papers), Hematopoietic Stem Cell Transplantation (6 papers) and Acute Myeloid Leukemia Research (5 papers). H.‐G. Mergenthaler is often cited by papers focused on Cancer Treatment and Pharmacology (7 papers), Hematopoietic Stem Cell Transplantation (6 papers) and Acute Myeloid Leukemia Research (5 papers). H.‐G. Mergenthaler collaborates with scholars based in Germany, Austria and Switzerland. H.‐G. Mergenthaler's co-authors include K. Possinger, M. Arning, Peter G. Dormer, Helmut König, U. Fink, H. Wilke, Michael Clemens, Andreas Schalhorn, Volker Heinemann and H. J. Illiger and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Annals of Neurology.

In The Last Decade

H.‐G. Mergenthaler

30 papers receiving 878 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
H.‐G. Mergenthaler Germany 12 543 212 206 173 155 33 903
Junning Cao China 16 553 1.0× 213 1.0× 381 1.8× 109 0.6× 71 0.5× 90 907
Hui-Qiang Huang China 22 819 1.5× 139 0.7× 740 3.6× 151 0.9× 150 1.0× 51 1.4k
Chueh‐Chuan Yen Taiwan 19 386 0.7× 377 1.8× 173 0.8× 69 0.4× 48 0.3× 58 930
Helen A. Bean Canada 13 258 0.5× 227 1.1× 286 1.4× 63 0.4× 99 0.6× 23 1.1k
L. Leong United States 16 648 1.2× 241 1.1× 144 0.7× 39 0.2× 45 0.3× 41 1.0k
Jun Miyauchi Japan 13 267 0.5× 177 0.8× 298 1.4× 116 0.7× 139 0.9× 40 804
Geoffrey Chong Australia 15 393 0.7× 117 0.6× 307 1.5× 179 1.0× 141 0.9× 59 769
Tong-Yu Lin China 22 586 1.1× 163 0.8× 461 2.2× 80 0.5× 93 0.6× 47 1.3k
H Weinstein United States 13 199 0.4× 235 1.1× 290 1.4× 80 0.5× 83 0.5× 24 720
Myung Hee Chang South Korea 17 385 0.7× 246 1.2× 205 1.0× 73 0.4× 49 0.3× 50 718

Countries citing papers authored by H.‐G. Mergenthaler

Since Specialization
Citations

This map shows the geographic impact of H.‐G. Mergenthaler's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by H.‐G. Mergenthaler with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites H.‐G. Mergenthaler more than expected).

Fields of papers citing papers by H.‐G. Mergenthaler

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by H.‐G. Mergenthaler. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by H.‐G. Mergenthaler. The network helps show where H.‐G. Mergenthaler may publish in the future.

Co-authorship network of co-authors of H.‐G. Mergenthaler

This figure shows the co-authorship network connecting the top 25 collaborators of H.‐G. Mergenthaler. A scholar is included among the top collaborators of H.‐G. Mergenthaler based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with H.‐G. Mergenthaler. H.‐G. Mergenthaler is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Gaidzik, Verena I., Richard F. Schlenk, Peter Paschka, et al.. (2011). DNMT3A mutations Predict for Inferior Outcome in NPM1-Wildtype and Molecular Unfavorable Cytogenetically-Normal Acute Myeloid Leukemia: A Study of the German-Austrian AMLSG. Blood. 118(21). 415–415. 2 indexed citations
2.
Beinert, T., H.‐G. Mergenthaler, Orhan Sezer, et al.. (2008). Hypoxie bei soliden Tumoren. DMW - Deutsche Medizinische Wochenschrift. 124(17). 534–540.
3.
Trappe, Ralf Ulrich, Sylvain Choquet, Petra Reinke, et al.. (2007). Salvage Therapy for Relapsed Posttransplant Lymphoproliferative Disorders (PTLD) With a Second Progression of PTLD After Upfront Chemotherapy: The Role of Single-Agent Rituximab. Transplantation. 84(12). 1708–1712. 30 indexed citations
4.
5.
6.
Eucker, Jan, Peter Schmid, Christian Jakob, et al.. (2002). The combination of fludarabine and cyclophosphamide results in a high remission rate with moderate toxicity in low-grade non-Hodgkinʼs lymphomas. Anti-Cancer Drugs. 13(9). 907–913. 8 indexed citations
7.
Brouwers, Adrienne H., U. Dörr, O. Lang, et al.. (2002). 131I-cG250 monoclonal antibody immunoscintigraphy versus [18F]FDG-PET imaging in patients with metastatic renal cell carcinoma: a comparative study. Nuclear Medicine Communications. 23(3). 229–236. 40 indexed citations
8.
Herrlinger, Ulrich, Martin Schabet, Wolfram Brugger, et al.. (2002). German Cancer Society Neuro‐Oncology Working Group NOA‐03 multicenter trial of single‐agent high‐dose methotrexate for primary central nervous system lymphoma. Annals of Neurology. 51(2). 247–252. 130 indexed citations
9.
Heinemann, Volker, H. Wilke, H.‐G. Mergenthaler, et al.. (2000). Gemcitabine and cisplatin in the treatment of advanced or metastatic pancreatic cancer. Annals of Oncology. 11(11). 1399–1403. 146 indexed citations
10.
Beinert, T., D. Binder, Martin Stuschke, et al.. (2000). Oxidativer pulmonaler Stress unter zytoreduktiver Therapie. Pneumologie. 54(5). 201–211. 1 indexed citations
11.
Beinert, T., D. Binder, Sabine Ziemer, et al.. (2000). Further evidence for oxidant-induced vascular endothelial growth factor up-regulation in the bronchoalveolar lavage fluid of lung cancer patients undergoing radio-chemotherapy. Journal of Cancer Research and Clinical Oncology. 126(6). 352–356. 18 indexed citations
12.
Sezer, Orhan, Peter Schmid, Michael Hallek, et al.. (1999). Eosinophilia during fludarabine treatment of chronic lymphocytic leukemia. Annals of Hematology. 78(10). 475–477. 9 indexed citations
13.
Schmid, Peter, et al.. (1999). Prolonged infusion of gemcitabine in stage IV breast cancer. Anti-Cancer Drugs. 10(6). 525–532. 40 indexed citations
14.
Lüftner, Diana, et al.. (1998). Gemcitabine plus dose-escalated epirubicin in advanced breast cancer: results of a phase I study. Investigational New Drugs. 16(2). 141–146. 22 indexed citations
15.
Busch, F.W., et al.. (1992). Myelopoiesis in vitro is suppressed by hepatitis A virus. Annals of Hematology. 64(S1). A132–A136. 5 indexed citations
16.
Mergenthaler, H.‐G.. (1992). Analysis of human The International Journal of Cell Cloning by a miniaturized micro long-term bone marrow culture system. Stem Cells. 10(S1). 171–173. 1 indexed citations
17.
Mergenthaler, H.‐G. & Peter G. Dormer. (1991). Hematopoiesis Studied by Limiting Dilution of either Hematopoietic Stem or Stromal Cells in Two‐Step Human Micro Long‐Term Bone Marrow Cultures. Annals of the New York Academy of Sciences. 628(1). 172–174. 1 indexed citations
18.
Mergenthaler, H.‐G. & Peter G. Dormer. (1990). In vitro hemopoiesis in human micro long-term bone marrow cultures recharged with either allogeneic, T-cell-depleted allogeneic, or syngeneic bone marrow cells. Annals of Hematology. 60(4). 228–232. 2 indexed citations
19.
Dormer, Peter G., Lothar Hültner, & H.‐G. Mergenthaler. (1990). Proliferation and Maturation of Human Bone Marrow Cellsin Infectious Diseases. Pathology - Research and Practice. 186(1). 145–149. 4 indexed citations
20.
Mergenthaler, H.‐G., et al.. (1988). Carcinoma-Associated Hemolytic-Uremic Syndrome in a Patient receiving 5-Fluorouracil-Adriamycin-Mitomycin C Combination Chemotherapy. Oncology. 45(1). 11–14. 16 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Junning Cao Breakdown of academic impact, for papers by Hui-Qiang Huang Breakdown of academic impact, for papers by Chueh‐Chuan Yen Breakdown of academic impact, for papers by Helen A. Bean Breakdown of academic impact, for papers by L. Leong Breakdown of academic impact, for papers by Jun Miyauchi Breakdown of academic impact, for papers by Geoffrey Chong Breakdown of academic impact, for papers by Tong-Yu Lin Breakdown of academic impact, for papers by H Weinstein Breakdown of academic impact, for papers by Myung Hee Chang
Rankless by CCL
2026